As part of our ongoing venture to develop new synthetic
methodologies based on the photochemical reactions of
azides,10 we report herein a new cyclization reaction of
iminyl radicals generated by the visible light induced and
NBS-mediated reaction of 2-azido-N-phenylacetamides
(1) (Scheme 1). The reactions afforded two kinds of
products, quinoxalin-2-ones (2) and spiro[cyclohexen-
1,20-imidazol]-40-ones (3 or 4), in different proportions.
Quinoxalin-2(1H)-ones and spiro[cyclohexene-1,20-
imidazol]-40-ones are important heterocycles displaying
a wide range of biological and medicinal activities, and
are scaffolds for drug-related molecules. For example,
compounds I and II show antithrombotic and antitumor
activity;11 compounds III are glycine transporter inhibi-
tors;12a IV are antagonists of CGRP receptors12b (Figure 1).
Many reports have been found for the synthesis of
quinoxalin-2-ones. The traditional methods for assem-
bling quinoxalin-2-ones are based on the condensation of
a substituted o-phenylenediamine with an R-ketone acid
ester or R-aldehyde acid ester.13a,b In recent years, a num-
ber of new methods have been developed. For example,
Bao reportedthesynthesis of quinoxalin-2-onesbycopper-
catalyzed cascade reaction of 2-halo-N-(2-halophenyl)-
acetamides with TsNH2;13c Leardini and Spagnolo re-
ported the synthesis of quinoxalin-2-ones by tributyltin
hydride mediated radical cyclization reaction of o-iodo-N-
methylanilides.13d Compared with the synthesis of quinoxalin-
2-ones, few reports are avaliable concerning the synthe-
sis of spiro[cyclohexene-1,20-imidazol]-40-ones and similar
compounds. Recently, Chiba and co-workers described a
copper-catalyzed synthesis of spiro[cyclohexadiene-1,20-
imidazol]-4,40-diones by the cyclization of R-azido-N-
arylamides under an oxygen atmosphere.14 The new
method reported here is an efficient and simple proce-
dure for the synthesis of both quinoxalin-2-ones and
spiro[cyclohexadiene-1,20-imidazol]-40-ones.
Scheme 1. Photoreaction of 2-Azido-N-phenylacetamides with
NBS
The initial pilot efforts were focused on the optimization
of light-induced and NBS-mediated cyclization of 2-azido-
N-phenylacetamide (1a). Previous NBS-related articles
suggested the formation of radicals from NBS could be
achieved under both UV irradiation15 and visible light
irradiation.16 It was found, however, that only visible light
irradiation was suitable for the cyclization of 1a to afford
2a and 3a in dichloromethane (DCM) at room tempera-
ture (Table 1). Under UV irradiation, the reaction resulted
in formation of complex products. Control experiment
showed that no reaction was detected under reflux in dark
in DCM, indicating that irradiation was essential to this
reaction. Under visible light irradiation, complete conver-
sion of 1a could be achieved when 2.0 equiv of NBS was
used (entry 3, Table 1). It was noticed that the product 3a
was always detected no matter how much NBS was used
(entries 1ꢀ3), and the proportion of 2a and 3a did not vary
greatly, suggesting that 2a and 3a were formed at the same
time.
Moreover, various solvents were also examined, and
DCM proved to be the best choice (entries 3ꢀ6, Table 1).
Under the optimal reactionconditions(entry 3, Table1),
the photoreactions of a group of 2-azido-N-phenylacet-
amides (1bꢀh) bearing different substituents on both phenyl
ring and nitrogen atom withNBS wereexamined(Table2).
All photoreactions of 1aꢀh could afford the cycliza-
tion products, but both the proportion and the yields of
Figure 1. Some pharmaceutically important quinoxalin-2-one
and spiro[cyclohexene-1,20-imidazol]-40-one derivatives.
(9) (a) Praly, J.-P.; Di Stefano, C.; Somsak, L.; Descotes, G. J. Chem.
Soc., Chem. Commun. 1992, 200. (b) Praly, J.-P.; Senni, D.; Faure, R.;
Descotes, G. S. Tetrahedron 1995, 51, 1697.
(10) (a) Shi, Z.; Ren, Y.; Li, B.; Lu, S.; Zhang, W. Chem. Commun.
2010, 46, 3973. (b) Ren, Y.; Wang, X.; Wang, W.; Li, B.; Shi, Z.; Zhang,
W. Tetrahedron Lett. 2011, 52, 192. (c) Li, Z.; Wang, W.; Zhang, X.; Hu,
C.; Zhang, W. Synlett 2013, 24, 73.
(11) (a) Jacobsen, E. J.; Stelzer, L. S.; TenBrink, R. E.; Belonga, K. L.;
Carter, D. B.; Im, H. K.; Im, W. B.; Sethy, V. H.; Tang, A. H.; Zhong, W. Z.;
Mickelson, J. W. J. Med. Chem. 1999, 42, 1123. (b) Ries, U. J.; Priepke,
H. W. M.; Hauel, N. H.; Haaksma, E. E. J.; Stassen, J. M.; Wienen, W.; Nar,
H. Bioorg. Med. Chem. Lett. 2003, 13, 2297. (c) Lawrence, D. S.; Copper,
J. E.; Smith, C. D. J. Med. Chem. 2001, 44, 594. (d) Carta, A.; Sanna, P.;
Gherardini, L.; Usai, D.; Zanetti, S. Farmaco 2001, 56, 933.
ꢀ
(13) (a) Gris, J.; Glisoni, R.; Fabian, L.; Fernandez, B.; Moglioni,
A. G. Tetrahedron Lett. 2008, 49, 1053. (b) Ballini, R.; Gabrielli, S.;
Palmieri, A. Synlett 2009, 965. (c) Chen, D.; Wang, Z.; Bao, W. J. Org.
Chem. 2010, 75, 5768. (d) Bencivenni, G.; Lanza, T.; Leardini, R.;
Minozzi, M.; Nanni, D.; Spagnolo, P.; Zanardi, G. J. Org. Chem.
2008, 73, 4721.
(14) Chiba, S.; Zhang, L.; Lee, J. Y. J. Am. Chem. Soc. 2010, 132,
7266.
(15) (a) Chow, Y. L.; Zhao, D. C. J. Org. Chem. 1989, 54, 530–534.
(b) Lu, F. L.; Naguib, Y. M. A.; Kitadani, M.; Chow, Y. L. Can. J.
Chem. 1979, 57, 1967.
(12) (a) Willam, D. A.; Alan, P. R. PCT Int. Appl. 2007, WO
2007014762 A2 20070208. (b) Selnick, H. G.; Wood, M. R.; McWherter,
M.; Hills, I. D.; Stump, C. A. PCT Int. Appl. 2010, WO 2010077752 A1
20100708.
(16) Kim, S. S.; Choi, S. Y.; Kang, C. H. J. Am. Chem. Soc. 1985, 107,
4234.
Org. Lett., Vol. 15, No. 15, 2013
3821